Pharma stock under Rs 55 in focus as company reports a 38.1 per cent revenue surge & 39.07 per cent jump in PAT
From Rs 43.42 per share (52-week low) to Rs 50.40 per share, the stock is up by 16 per cent.
Today, shares of Sigachi Industries plunged 0.65 per cent to Rs 50.40 per share from its previous closing of Rs 50.73 with an intrtaday high of Rs 51.88 and an intraday low of Rs 50.10. The company has a market cap of Rs 1,650 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
Sigachi Industries Limited, publicly listed in NSE and BSE, is a globally recognized pharmaceutical company known for its unwavering commitment to delivering high-quality excipients, vitamin mineral nutrient blends, APIs, and O&M services. With over 33 years of industry experience, Sigachi has emerged as a trusted partner for pharmaceutical and nutraceutical companies spread across 62 countries. The company's diverse product portfolio is manufactured in 5 multilocational facilities present in Telangana, Gujarat and Karnataka which hold global standard certifications. Being headquartered in Hyderabad, Sigachi Industries Limited has subsidiaries in the US and UAE.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
The company announced positive Quarterly Results (Q2FY25) and half-yearly results (H1FY24) for the financial year 2024. According to quarterly results, revenue increased by 38.10 per cent to Rs 137 crore, EBITDA increased by 36.91 per cent to Rs 29.3 crore and PAT increased by 39.07 per cent to Rs 21 crore in Q2FY25 compared to Q2FY24. In its half-yearly results, revenue increased by 26.53 per cent to Rs 232.7 crore, EBITDA increased by 33.33 per cent to Rs 50.40 crore and PAT increased by 29.61 per cent to Rs 33.7 crore in H1FY25 compared to H1FY24.
From Rs 43.42 per share (52-week low) to Rs 50.40 per share, the stock is up by 16 per cent. Investors should keep an eye on this small-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.